AstraZeneca Forecast, price target & analysts
AstraZeneca Target price 2025 - Analyst rating & recommendation
AstraZeneca Classifications & Recommendation:
AstraZeneca Price Target
| Target Price | GBP137.10 |
| Price | GBP104.44 |
| Potential | 31.27% |
| Number of Estimates | 24 |
| 24 Analysts have issued a price target AstraZeneca 2026 . The average AstraZeneca target price is GBP137.10. This is 31.27% higher than the current stock price. The highest price target is GBP169.92 62.69% , the lowest is GBP102.80 1.57% . | |
| A rating was issued by 32 analysts: 28 Analysts recommend AstraZeneca to buy, 4 to hold and 0 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
| Analyst Estimates: Analysts believe that the AstraZeneca stock has an average upside potential 2026 of 31.27% . Most analysts recommend the AstraZeneca stock at Purchase. |
Sales and Margin forecast 2025, 2026 to 2029
24 Analysts have issued a sales forecast AstraZeneca 2025 . The average AstraZeneca sales estimate is GBP43.3b . This is 2.41% higher than the revenue of the last 12 months(TTM). The highest sales forecast is GBP44.9b 6.17% , the lowest is GBP40.6b 3.94% .
This results in the following potential growth metrics:
Revenue Estimates
| 2024 | GBP42.3b | 14.82% |
|---|---|---|
| 2025 | GBP43.3b | 2.39% |
| 2026 | GBP46.2b | 6.59% |
| 2027 | GBP48.8b | 5.57% |
| 2028 | GBP52.0b | 6.67% |
| 2029 | GBP54.8b | 5.41% |
18 Analysts have issued an AstraZeneca EBITDA forecast 2025. The average AstraZeneca EBITDA estimate is GBP15.0b . This is 9.07% higher than the EBITDA of the last 12 months(TTM). The highest EBITDA forecast is GBP17.9b 30.09% , the lowest is GBP12.5b 9.54% .
This results in the following potential growth metrics and future EBITDA Margins:
EBITDA Estimates
| 2024 | GBP14.0b | 21.08% |
|---|---|---|
| 2025 | GBP15.0b | 7.46% |
| 2026 | GBP16.8b | 11.75% |
| 2027 | GBP18.5b | 10.25% |
| 2028 | GBP20.2b | 9.14% |
| 2029 | GBP24.0b | 18.86% |
EBITDA Margin
| 2024 | 33.02% | 5.44% |
|---|---|---|
| 2025 | 34.66% | 4.97% |
| 2026 | 36.33% | 4.82% |
| 2027 | 37.94% | 4.43% |
| 2028 | 38.82% | 2.32% |
| 2029 | 43.78% | 12.78% |
16 AstraZeneca Analysts have issued a net profit forecast 2025. The average AstraZeneca net profit estimate is GBP7.4b . This is 34.20% higher than the net profit for the last 12 months(TTM). The highest net profit forecast is GBP10.4b 88.32% , the lowest is GBP4.9b 11.83% .
This results in the following potential growth metrics and future Net Margins:
Net Profit Estimates
| 2024 | GBP5.5b | 14.89% |
|---|---|---|
| 2025 | GBP7.4b | 34.58% |
| 2026 | GBP9.0b | 21.40% |
| 2027 | GBP10.1b | 12.43% |
| 2028 | GBP11.4b | 12.80% |
| 2029 | GBP14.1b | 23.42% |
Net Margin
| 2024 | 13.01% | 0.05% |
|---|---|---|
| 2025 | 17.10% | 31.46% |
| 2026 | 19.47% | 13.86% |
| 2027 | 20.74% | 6.52% |
| 2028 | 21.93% | 5.74% |
| 2029 | 25.68% | 17.10% |
Earnings per share, P/E ratio and EV/sales Estimates 2025, 2026 to 2029
16 Analysts have issued a AstraZeneca forecast for earnings per share. The average AstraZeneca EPS is GBP4.78 . This is 34.27% higher than earnings per share in the financial year 2024. The highest EPS forecast is GBP6.70 88.20% , the lowest is GBP3.14 11.80% .
This results in the following potential growth metrics and future valuations:
Earnings Per Share
| 2024 | GBP3.55 | 14.89% |
|---|---|---|
| 2025 | GBP4.78 | 34.65% |
| 2026 | GBP5.80 | 21.34% |
| 2027 | GBP6.52 | 12.41% |
| 2028 | GBP7.36 | 12.88% |
| 2029 | GBP9.08 | 23.37% |
P/E ratio
| Current | 29.34 | 17.02% |
|---|---|---|
| 2025 | 21.86 | 25.49% |
| 2026 | 18.01 | 17.61% |
| 2027 | 16.02 | 11.05% |
| 2028 | 14.20 | 11.36% |
| 2029 | 11.50 | 19.01% |
Based on analysts' sales estimates for 2025, the AstraZeneca stock is valued at an EV/Sales of 4.19 and an P/S ratio of 3.74 .
This results in the following potential growth metrics and future valuations:
EV/Sales
| Current | 4.29 | 15.72% |
|---|---|---|
| 2025 | 4.19 | 2.25% |
| 2026 | 3.93 | 6.18% |
| 2027 | 3.73 | 5.28% |
| 2028 | 3.49 | 6.25% |
| 2029 | 3.31 | 5.13% |
P/S ratio
| Current | 3.83 | 16.88% |
|---|---|---|
| 2025 | 3.74 | 2.35% |
| 2026 | 3.51 | 6.18% |
| 2027 | 3.32 | 5.28% |
| 2028 | 3.11 | 6.25% |
| 2029 | 2.95 | 5.13% |
Current AstraZeneca Upgrades & Downgrades
| Analyst | Rating | Action | Date |
|---|---|---|---|
| Berenberg Bank |
➜
Buy
|
Unchanged | Mar 26 2025 |
| Shore Capital |
➜
Buy
|
Unchanged | Mar 07 2025 |
| JP Morgan Cazenove |
➜
Overweight
|
Unchanged | Feb 19 2025 |
| Berenberg Bank |
➜
Buy
|
Unchanged | Jan 27 2025 |
| Berenberg Bank |
➜
Buy
|
Unchanged | Jan 06 2025 |
| JP Morgan Cazenove |
➜
Overweight
|
Unchanged | Nov 22 2024 |
| JP Morgan Cazenove |
➜
Overweight
|
Unchanged | Nov 07 2024 |
| Analyst Rating | Date |
|---|---|
|
Unchanged
Berenberg Bank:
➜
Buy
|
Mar 26 2025 |
|
Unchanged
Shore Capital:
➜
Buy
|
Mar 07 2025 |
|
Unchanged
JP Morgan Cazenove:
➜
Overweight
|
Feb 19 2025 |
|
Unchanged
Berenberg Bank:
➜
Buy
|
Jan 27 2025 |
|
Unchanged
Berenberg Bank:
➜
Buy
|
Jan 06 2025 |
|
Unchanged
JP Morgan Cazenove:
➜
Overweight
|
Nov 22 2024 |
|
Unchanged
JP Morgan Cazenove:
➜
Overweight
|
Nov 07 2024 |
Discover more stocks with a high price target
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
